Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Viral Infectious Diseases and Gene Expression in Insects, Virus-based gene therapy research, and Immune Cell Function and Interaction.
Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment
Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse
Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment.
Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma
A subset of patients achieve prolonged remission beyond 3–5 years with FHVH33-CD8BBZ BCMA CAR T-cells for RRMM
Current understanding and management of CAR T cell-associated toxicities.
Chimeric antigen receptor T cell therapy for autoimmune disease.
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia
FDA approval of the first cellular therapy for a solid (non-hematologic) cancer
Long-term outcomes following CAR T cell therapy: what we know so far.
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions
Off-the-shelf CAR T cells for multiple myeloma.
Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
CAR T cell therapies for patients with multiple myeloma.
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days.
Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.